Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of advanced training skills among GPs: a systematic review.

Rural and remote health·2026
Same author

DrugUtilisation: An R Package to Support Drug Utilisation Research Using the OMOP Common Data Model.

Pharmacoepidemiology and drug safety·2026
Same author

Comparison of methods for assessing effects of risk factors on disease progression in Mendelian randomization under index event bias.

American journal of human genetics·2026
Same author

Barriers and Enablers in Implementing Technology-Enabled Care for Older Adults in Rural and Remote Settings: A Scoping Review.

International journal of environmental research and public health·2026
Same author

Prescription cascades associated with acetylcholinesterase inhibitors use: a high-throughput sequence symmetry analysis.

Age and ageing·2026
Same author

Targeted Connectomic Neuromodulation of the Orbitofrontal Cortex To Treat Obsessive-Compulsive Disorder.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jan 15, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.6K

Phosphodiesterase-5 Inhibition and Alzheimer's Disease Risk: A Mendelian Randomisation Study.

Marta Alcalde-Herraiz1, Benjamin Woolf2,3,4, Junqing Xie1

  • 1Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.

Aging Cell
|October 13, 2025
PubMed
Summary

Phosphodiesterase 5 (PDE5) inhibitors may not reduce Alzheimer's disease (AD) risk. Genetic analysis found no causal link between PDE5 inhibition and AD, suggesting limited neuroprotective effects for cognitive decline.

Keywords:
Alzheimer's diseaseMendelian randomisationdementiaphosphodiesterase‐5sildenafil

More Related Videos

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.4K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.9K

Related Experiment Videos

Last Updated: Jan 15, 2026

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.6K
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.4K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.9K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Preclinical research suggests Phosphodiesterase 5 (PDE5) inhibition might improve cognitive function.
  • Observational studies on PDE5 inhibitors and Alzheimer's disease (AD) risk present conflicting results.

Purpose of the Study:

  • To investigate the potential causal effect of PDE5 inhibition on Alzheimer's disease (AD) risk.
  • To address inconsistencies in previous research using a robust genetic approach.

Main Methods:

  • A two-sample cis-Mendelian Randomisation (MR) analysis was conducted.
  • Data from four genome-wide association studies (GWAS) for AD were utilized for triangulation.
  • Sex-stratified MR analysis using UK Biobank data assessed potential sex-specific effects.

Main Results:

  • No significant causal association was detected between PDE5 inhibition and the risk of developing Alzheimer's disease (AD).
  • Sex-stratified analyses did not reveal any sex-specific protective effects of PDE5 inhibition against AD.

Conclusions:

  • The study suggests that PDE5 inhibitors are unlikely to reduce the risk of Alzheimer's disease (AD).
  • Genetic evidence does not support a causal role for PDE5 inhibition in AD prevention.
  • Further research is warranted to fully elucidate the impact of PDE5 inhibitors on AD risk.